Adverse reactions

Table showing summary of adverse reactions observed in ≥ 10% of patients treated with TECARTUS™ in ZUMA-2 (N=82) Table showing summary of adverse reactions observed in ≥ 10% of patients treated with TECARTUS™ in ZUMA-2 (N=82)

Pinch to zoom

Grade 3 or 4 lab abnormalities

Table showing grade 3 or 4 laboratory abnormalities occurring in ≥ 10% of patients in ZUMA-2 following TECARTUS™ infusion (N=82). Table showing grade 3 or 4 laboratory abnormalities occurring in ≥ 10% of patients in ZUMA-2 following TECARTUS™ infusion (N=82).

Pinch to zoom

Prolonged cytopenias have occurred following treatment with TECARTUS1

  • Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and TECARTUS infusion
  • At Day 30, 55% of patients had unresolved Grade 3 or higher cytopenias
    • 38% with thrombocytopenia
    • 37% with neutropenia
    • 17% with anemia

MCL=mantle cell lymphoma; R/R=relapsed or refractory.

Reference: 1. TECARTUS™ (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2020.